DFJ InCube Ventures is a life science venture capital firm focused on investing in extraordinary innovations that solve unmet clinical needs for large patient populations. The fund is built around Mir Imran, one of the leading healthcare innovators. Under Mir's leadership, DFJ InCube Ventures has access to ventures formed by InCube Labs â€“ a multi-disciplinary research lab that has been a highly productive source of medical device companies. Mir and InCube Labs have formed 20 companies over the past 25 years, creating a series of multi-billion dollar markets along the way.  In addition to Mir, proven healthcare entrepreneurs and investors Andrew Farquharson and Wayne Roe serve as managing partners of the fund.  DFJ InCube Ventures managing partners work closely with entrepreneurs to commercialize breakthroughs grounded in clinical need and protected by strong intellectual property. Their experienced team also actively helps young companies mitigate technical, clinical and reimbursement risks. Most importantly, the team collaborates with entrepreneurs to determine the most effective path for bringing innovations to life in a way that dramatically improves clinical outcomes.  The fund's current portfolio includes companies that are developing novel treatment approaches in clinical areas such as atrial fibrillation, epilepsy, gastro intestinal surgery, iron-deficiency anemia, hemorrhagic stroke and metabolic disorders.

InCube Ventures

Bayer is an enterprise with core competencies in the life science fields of healthcare and nutrition. They design their products and services to help people and the planet thrive by supporting efforts to address unprecedented challenges. Their businesses include pharmaceuticals, consumer health, and crop science. They focus on developing and commercializing products and solutions based on scientific knowledge.

Bayer

Humboldt Fund is an investment firm that seeks to invests in bio revolution companies.

Humboldt Fund

Sozo Ventures was formed in 2011 to invest in and support IT ventures with their global expansion. We invest in category leaders in advanced data technologies, ecommerce, enterprise cloud, fintech, IOT and healthcare IT, among other emerging sectors. We are structured to connect the most ambitious entrepreneurial teams with the world's most advanced and respected customers and distributors. We are at our best when we can share our expertise well before expansion strategies are set.

Sozo Ventures

HOF Capital is a global multistage VC firm with $1 billion in AUM that partners with ambitious entrepreneurs from idea to IPO.

HOF Capital

Agent Capital

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. The company invests in companies with promising technologies and products.

RA Capital Management

Leaps by Bayer invests in paradigm-shifting advances in the life sciences and specializes in the fields of biotechnology, agriculture, and scientific breakthrough. The firm's approach is making significant and sustained investments in disruptive biotechnologies that could have the greatest impact on humanity. It was founded in 2015 and headquartered in Leverkusen, Nordrhein-Westfalen.

Leaps by Bayer

Farallon Capital Management, L.L.C. is an American capital management firm that manages funds on behalf of institutions and individuals with significant capital. Based in San Francisco, the firm was founded by Thomas F. Steyer in March of 1986. As of September 2008, it has around 150 employees.  While it invests across the capital structure and in all asset classes, a large amount of its investments are in risk arbitrage, restructuring and recapitalization. Investments include public and private debt and equity securities, direct investments in private companies, and real estate. Farallon's real estate investments span the United States, Europe, Latin America and India.

Farallon Capital Management

PFM Health Sciences is an investment management firm specializing in global healthcare strategies. The firm was founded in 2004 and is headquartered in San Francisco, California, United States.

PFM Health Sciences

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products.  Bristol Myers Squibb focuses on areas such as oncology, cardiovascular, immunoscience, and fibrosis to develop therapies that address significant unmet medical needs. The company's research and development efforts are centered around discovering new drugs and advancing existing ones to improve patient outcomes. BMS has a diverse portfolio of medicines, including several blockbuster drugs used in the treatment of cancer and other diseases. The company is committed to advancing the science of medicine to help people fight serious diseases and improve their quality of life.

Bristol-Myers Squibb

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies.  The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations.  Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders.  The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors.  The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.

Frazier Healthcare Partners

Novo Holdings is a holding company specializing in life science investors with a focus on creating long-term value.

Novo Holdings

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells.  Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology.  Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

Moderna

Pura Vida Investments is a fundamentally driven, market neutral healthcare-focused investment vehicle. The objective of the firm is to identify and capitalize on structural changes in the healthcare landscape and on inflections in company specific valuations. The firm strives to look past day-to-day volatility and to hone in on major value shifts over the medium to longer term.  The firm’s portfolio is managed by Efrem Kamen and Doron Junger MD and is run in a market neutral fashion, investing across most areas of healthcare, including medical devices, biotechnology, pharmaceuticals, tools, life sciences and healthcare services. The Fund has an optional 10% allocation to designated investments, allowing participation in private and certain illiquid public securities, which is managed by Frank Litvack MD.

Pura Vida Investments

Eventide Asset Management, LLC is a Boston-based investment adviser practicing ''investing that makes the world rejoice®.''​ Founded in 2008, Eventide's vision is to serve individuals, financial advisors, and institutions by providing high-performance investments that we believe create compelling value for the global common good.

Eventide

Irving was founded in 2009 as a dedicated equity fund focused on disruptive technology and high growth opportunities and has since expanded into credit and private investments. The fund looks to form meaningful relationships with companies by offering its capital, expertise, and connections to promote growth and return on investment. Irving has been involved in several successful private exits and is a trusted advisor and LP in Venture Capital funds.

Irving Investors

Millennium Management is an investment management company. They seek an array of investment strategies across industry sectors, asset classes, and geographies. Their entrepreneurial environment enables them to manage their investment processes. They also seek to accelerate by providing sophisticated resources and technology.

Millennium Management

Marshall Wace is a hedge fund manager specializing in global long/short equity. The firm has investment management offices in London; New York; and Hong Kong.  Marshall Wace LLP was named Management Firm of the Year by the EuroHedge Awards 2011, reflecting the strong performance delivered by a number of our funds during the year. The firm is dedicated to the objective of providing its clients with a persistent, risk-adjusted return on their investment. Through a range of products, investors can select funds offering variable sources of alpha and beta, in different combinations, from equity markets around the world. Marshall Wace brings together two distinct but complementary approaches to asset management. First, traditional, fundamental long/short investing grounded in stock-specific analytical research, and secondly, Marshall Wace TOPS (‘MW TOPS’), the pioneering, and proprietary, systematic, alpha capture strategy.

Marshall Wace

Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.

Surveyor Capital

Deep Track Capital is an investment firm focused exclusively on the life sciences and biotech industry. It forges partnerships with the management teams of innovative public and pre-IPO biotechnology companies. It seeks to invest its time and expertise, as well as its network, for the benefit of the partners in addition to capital. The firm intends to lead transactions while forming large syndicates, as well as to participate in rounds led by other qualified investors.

Deep Track Capital

Yaya Capital is a Venture capital and Private equity firm.

Yaya Capital

Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies. It was created by George Petrocheilos and Dr. Jacob Vogelstein in 2020.

Catalio Capital Management

SymBiosis LLC is a biotech-focused investment vehicle.

SymBiosis LLC

Metagenomi

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.

<div>Metagenomi specializes in gene editing to develop novel therapeutics for oncology, metabolic, and genetic diseases, using its proprietary gene editing discovery platform based on metagenomics&mdash;environment-derived genetic materials or microbes. This platform enables highly precise editing compared with existing gene editing technologies. The company&rsquo;s discovery engine leverages AI-powered cloud computing and a comprehensive database of metagenomic data containing 310 trillion base pairs (equivalent to more than 34,000x human genomes) to identify more than 100 novel nuclease families.&nbsp;</div>

Reinventing gene therapies with next-generation technologies

Human Gene Editing

Chardan Capital Maintains Buy on Metagenomi, ...

Moderna partnered with Metagenomi to develop in vivo therapeutics for serious genetic diseases, by leveraging Moderna's delivery technologies and Metagenomi's gene editing tools.

Companies that develop novel therapeutics based on other types of gene editing technologies including TALEN and ZFN

<div>
 
 Metagenomi specializes in gene editing to develop novel therapeutics for oncology, metabolic, and genetic diseases, using its proprietary gene editing discovery platform based on metagenomics&mdash;environment-derived genetic materials or microbes. This platform enables highly precise editing compared with existing gene editing technologies. The company&rsquo;s discovery engine leverages AI-powered cloud computing and a comprehensive database of metagenomic data containing 310 trillion base pairs (equivalent to more than 34,000x human genomes) to identify more than 100 novel nuclease families.&nbsp;
 
 
 Metagenomi&rsquo;s clinical pipeline consists of 11 in vivo (gene editing done inside the body) therapeutics targeting metabolic and genetic disorders such as hemophilia A and cystic fibrosis. The company was also developing two ex vivo (gene editing done in a specialized laboratory and returned to the body) cell therapy programs focused on immuno-oncology and autoimmune indications. As of March 2024, all of the company&rsquo;s programs were in the preclinical stages .&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnered with other biotech and pharmaceutical companies to offer its platform, including with 
 <a href="https://www.businesswire.com/news/home/20220615005392/en/Affini-T-Therapeutics-Metagenomi-Announce-Next-Generation-Gene-Editing-Partnership-to-Advance-Cell-Therapies-for-Solid-Tumor-Patients#:~:text=Patients%20%7C%20Business%20Wire-,Affini%2DT%20Therapeutics%20%26%20Metagenomi%20Announce%20Next%2DGeneration%20Gene%20Editing,Therapies%20for%20Solid%20Tumor%20Patients">
 Affini-T Therapeutics
 </a>
 (January 2022) to jointly develop ex vivo cell therapies for solid tumor, 
 <a href="https://metagenomi.co/press/metagenomi-and-moderna-establish-collaboration-to-develop-next-generation-in-vivo-gene-editing-therapeutics/">
 Moderna
 </a>
 (November 2021) to develop in vivo therapies for undisclosed targets, and 
 <a href="https://metagenomi.co/press/vor-biopharma-and-metagenomi-to-collaborate/">
 Vor Biopharma
 </a>
 (August 2020) to develop hematopoietic stem cell-based therapies for blood cancers such as acute myeloid leukemia.
 
 
 Funding and financials
 
 
 In its latest extended 
 <a href="https://sp-edge.com/updates/15527">
 Series B
 </a>
 funding round in January 2023, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, Metagenomi raised USD 100 million, bringing the company&rsquo;s total Series B funds to USD 275 million. The new funds were to be used to advance its lead programs through preclinical development and into clinical proof-of-concept studies. Having raised a total of USD 457 million since inception in 2018, the company has also secured investments from Moderna Therapeutics, Leaps by Bayer, and Bristol-Myers Squibb. 
 
</div>

<div>
 
 Editas Medicine specializes in gene editing to develop novel therapeutics for a variety of areas including oncology, ocular diseases, and blood diseases. It leverages the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, specifically Cas9 and Cas12a enzymes.&nbsp;
 
 
 The company develops both in vivo (gene editing done inside the body) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapeutics. As of March 2024, Editas has seven gene editing programs in its pipeline.&nbsp;
 
 
 One of the company&rsquo;s candidates was in the late clinical trial stages as of March 2024. The Phase I/II clinical trials on Editas&rsquo; in vivo gene editing therapy EDIT-101 have been ongoing since 2019 and the company announced that it had achieved proof of concept and identified a responder population in November 2022. For the first time ever (in April 2022), the company delivered its experimental in vivo CRISPR therapy to a 
 <a href="https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-dosing-first-pediatric-patient">
 pediatric patient
 </a>
 to treat Leber congenital amaurosis 10 (LCA10), an inherited early childhood eye disease. Its ex vivo gene editing therapy EDIT-301 holds two rare pediatric disease designations granted by the FDA for transfusion-dependent beta-thalassemia and sickle cell disease. The candidate also received 
 <a href="https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-receives-fda-orphan-drug-designation-edit-301">
 orphan drug designation
 </a>
 in May 2022 for beta-thalassemia.
 
 
 Key customers and partnerships
 
 
 Founded in September 2013, Editas has secured several collaborations with other pharmaceutical and drug developers including 
 <a href="https://www.catalent.com/catalent-news/catalent-enters-into-strategic-partnership-with-editas-medicine-to-support-gene-editing-medicine-pipeline/">
 Catalent
 </a>
 (for therapy development and manufacturing support),
 <a href="https://ir.editasmedicine.com/news-releases/news-release-details/adverum-biotechnologies-and-editas-medicine-announce">
 Adverum Biotechnologies 
 </a>
 (to develop technologies to deliver gene editing medicines to the eye), 
 <a href="https://www.askbio.com/editas-medicine-and-askbio-enter-strategic-research-collaboration-to-explore-in-vivo-delivery-of-genome-editing-medicines-to-treat-neurological-diseases/">
 Asklepios BioPharmaceutical
 </a>
 (AskBio) (to research in vivo gene editing therapies for neurological diseases),
 <a href="https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-and-bluerock-therapeutics-enter-strategic">
 BlueRock Therapeutics
 </a>
 (to develop medicines by combining cell therapy and gene editing technologies), and big pharma such as Bristol-Myers Squibb (to develop cell therapies for oncology).&nbsp;
 
 
 The company expanded its partnership with Azzur Cleanrooms on Demand (COD) in July 2023 with regard to continuing to manufacture Editas' candidate EDIT-301. 
 
 
 Funding and financials
 
 
 The company last raised funds in June 2023 when the company raised USD 125 million in a common stock offering. Editas Medicine did not disclose what the raised funds would be used for. The company has been listed on the Nasdaq since February 2016 and was the first CRISPR gene editing company to go public. 
 
</div>

Editas Medicine

<div>
 
 CRISPR Therapeutics specializes in developing gene editing-based novel therapeutics for a variety of areas including immuno-oncology and hemoglobinopathies. It leverages the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, specifically Cas9 enzymes, and focuses predominantly on treating somatic cells that do not transfer DNA to the next generations, preventing future generations from contracting a genetic disease.&nbsp;
 
 
 The company develops both in vivo (gene editing done inside the body) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapeutics. As of March 2024, the company had 18 drug candidates in its pipeline. 
 
 
 In a milestone event in November 2023, the company&rsquo;s gene-editing therapy exagamglogene autotemcel, CASGEVY 
 <a href="https://sp-edge.com/updates/24093">
 (exa-cel)
 </a>
 , developed with Vertex Pharmaceuticals to treat sickle-cell disease and beta-thalassemia, received the world&rsquo;s first authorization from the UK's Medicines and Healthcare products, Regulatory Agency (MHRA). In December 2023, it received FDA approval for patients aged 12 and older. The drug for beta-thalassemia patients is also nearing its market entry in the US, with the FDA&rsquo;s decision expected on March 30, 2024.&nbsp;
 
 
 
 
 
 Key customers and partnerships
 
 
 
 
 The company has secured strategic collaborations with several companies to co-develop and co-commercialize gene editing medicines that include 
 <a href="https://investors.vrtx.com/news-releases/news-release-details/vertex-pharmaceuticals-and-crispr-therapeutics-amend">
 Vertex Pharmaceuticals
 </a>
 (2015) to develop a therapy (CTX001) for various indications including beta-thalassemia, sickle cell disease, and Duchenne muscular dystrophy; and 
 <a href="https://viacyte.com/press-releases/crispr-therapeutics-and-viacyte-announce-strategic-collaboration-to-develop-gene-edited-stem-cell-derived-therapy-for-diabetes/">
 ViaCyte
 </a>
 (September 2018) to develop VCTX210, a regenerative medicine for diabetes.
 
 
 Big pharma Bayer also signed an option agreement in 2019 with the company to co-develop and co-commercialize two candidates, after entirely handing over the joint venture Casebia Therapeutics to CRISPR.&nbsp;&nbsp;
 
 
 
 
 
 Funding and financials
 
 
 
 
 Founded in 2013, CRISPR has been listed on the Nasdaq since 2016. For 2021, the company reported a revenue of USD 913.1 million earned via milestone payments, collaborations, and licensing.
 
 
 
 
 
</div>

CRISPR Therapeutics

<div>
 
 Intellia Therapeutics specializes in gene editing to develop novel therapeutics for various areas, including immuno-oncology, autoimmune, and genetic diseases. It leverages the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, specifically Cas9 enzymes.&nbsp;
 
 
 The company develops both in vivo (gene editing done inside the body) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapeutics. As of March 2024, it was working on 3 internal drug programs and four collaborative programs. As of March 2024, one program was in the late clinical stage, one program was in the early clinical stage, and five were in the research and preclinical stage. The company considers its lipid nanoparticle delivery system to be a key strength in minimizing genotoxicity risk and random insertion.
 
 
 Intellia acquired biotechnology company Rewrite Therapeutics for USD 45 million in February 2022 to leverage its gene editing and DNA-writing technologies. Intellia would also pay up to USD 155 million in additional milestone payments.
 
 
 
 
 
 Key customers and partnerships
 
 
 Intellia has partnered with a number of biotech and pharma companies, including: 
 1) Big pharma Novartis (January 2015), to research and co-develop CRISPR/Cas9-edited therapies to develop an ex-vivo treatment for sickle-cell disease and a number of undisclosed programs 
 2) Kyverna Therapeutics (January 2022), for the development of a next-generation CD19 CAR T-cell therapy for autoimmune diseases 
 3) ONK Therapeutics (February 2022), to develop engineered natural killer (NK) cell therapies for cancer treatment.&nbsp;
 
 
 In October 2023, the company expanded its research collaboration with 
 <a href="https://sp-edge.com/updates/22377">
 Regeneron Pharmaceuticals
 </a>
 (entered in April 2020) to develop gene-editing therapies for neurological and muscular diseases.
 
 
 
 
 
 Funding and financials
 
 
 Founded by Caribou Biosciences and Atlas Ventures in November 2014, Intellia has been listed on Nasdaq since May 2016. In 
 <a href="https://sp-edge.com/updates/15140">
 November 2022
 </a>
 , the company raised USD 300 million via an underwritten public offering&mdash;it did not disclose the purpose of the financing. For 2022, the company reported a revenue of ~USD 52&nbsp; million, earned through collaborations.
 
</div>

Intellia Therapeutics

<div>
 
 Based in the US and France, Cellectis develops off-the-shelf gene editing cancer immunotherapies based on allogeneic Chimeric Antigen Receptors T (CAR-T) cells dubbed UCARTs by leveraging the transcription activator-like effector nucleases (TALEN) technology.
 
 
 As of March 2024, the company had seven therapeutics in development; two targeting Leukemia, one for the treatment of non-Hodgkin lymphoma, one for Large B Cell Lymphoma, two for Multiple Myelnoma, and one for Renal Cell Carcinoma. Its Leukemia therapeutics were in Phase I of clinical trials, while its non-Hodgkin lymphoma solution was just entering Phase I of clinical trials. The company's therapeutics for Multiple Myeloma, another for Lymphoma, and Renal Cell Carcinoma, had been licensed out to other pharmaceutical companies.&nbsp;
 
 
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/23389">
 November 2023
 </a>
 , Cellectis entered into a partnership with AstraZeneca to accelerate the development of gene editing therapeutics, with a focus on oncology, immunology, and rare diseases.&nbsp;
 
 
 Cellectis also partnered with Primera in January 2023 to develop in-vivo gene therapies for mitochondrial disease. Through the partnership, both entities would collaborate to genetically edit mutations in mitochondrial DNA and develop an engineering toolbox that can be used to develop therapeutics for mitochondrial diseases. 
 
 
 
 
 
 
 Funding and financials
 
 
 The company entered into several strategic collaboration agreements with AstraZeneca in November 2023. These agreements included an investment agreement relating to an initial equity investment of USD 80 million by subscribing for 16 million ordinary shares. Cellectis stated that it planned to use the proceeds received to develop gene editing tools, for research and development expenses incurred in developing its programs, and other general corporate purposes.
 
 
 
</div>

Cellectis

Caribou Biosciences specializes in gene editing to develop novel therapeutics for hematologic oncology indications using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. It develops allogeneic off-the-shelf gene edited therapies based on Chimeric Antigen Receptors T (CAR-T) cells and CAR Natural Killer (CAR-NK) cells.The company leverages its proprietary platform CRISPR hybrid RNA-DNA (chRDNA), which uses hybrid guides—both ribonucleic acid (RNA) and DNA nucleotides—to edit DNA. As of March 2024, Caribou had four candidates in its clinical pipeline, of which its lead candidate CB-010, a CAR-T therapy to treat relapsed/refractory B cell non-Hodgkin lymphoma, was in the Phase I clinical trial stage (March 2024). Its other CAR-T candidates, CB-011 for the treatment of relapsed/refractory Multiple Myeloma and CB-012, for the treatment of relapsed/refractory Acute Myeloid Leukemia, were also in Phase I of clinical trials. Its alternate application for CB-010 to treat autoimmune diseases was still in the discovery stage.The company intended to extend ex vivo (gene editing done in a specialized laboratory and returned to the body) therapies toward other indications outside oncology and implement its Cas12a chRDNA platform in in vivo (gene editing done inside the body) applications.Key customers and partnershipsThe company entered into a partnership with big pharma company <a href="https://news.abbvie.com/news/press-releases/abbvie-and-caribou-biosciences-announce-collaboration-and-license-agreement-for-car-t-cell-products.htm">Abbvie </a>in February 2021 for licensing and co-development of two CAR-T therapies. Caribou also entered into licensing agreements with <a href="https://www.businesswire.com/news/home/20201118005128/en/Caribou-Biosciences-Announces-Licensing-Agreement-for-scFvs-Targeting-CD371-to-Enable-Development-of-Allogeneic-Cell-Therapies">Memorial Sloan Kettering Cancer Center </a>(MSKCC) (November 2020), Corteva Agriscience, and Intellia Therapeutics. It also has a sales and assignment agreement with ProMab Biotechnologies Inc. (February 2020).Funding and financialsCaribou Biosciences went public on the Nasdaq Global Select Market in July 2021 and raised USD 304 million. The IPO proceeds were earmarked to fuel the company’s clinical development. For 2021, it recorded revenue of USD 9.6 million earned through licensing and collaborations.The company last raised funding in July 2023, when it raised USD 125 million in an upsized underwritten public offering. Caribou did not disclose what the funds would be used for.

Caribou Biosciences

Companies that develop novel therapeutics based on the CRISPR/Cas9 gene-editing technology

Companies that develop systems that enable the diagnosis of gene-edited therapies. Also includes systems that deliver gene-editing components into the human body

Companies that offer their gene-editing platforms to other pharma companies to develop therapeutics

Companies that offer support services to gene-editing companies, which include genomic research companies, gene-editing component manufacturing, and designing tools

Startups in the hub develop gene-editing treatments to cater to specific patients and patient profiles

Genomics enables precise changes in the DNA sequence of living organisms to develop treatments

PROMINENT_CATEGORY

<div>
 
 Metagenomi, a California-based gene-editing company, has introduced its compact smart adenine base editors (ABEs). These are designed to fit into a single adeno-associated virus (AAV) for more efficient gene editing. The reveal took place at the American Institute of Chemical Engineers (AIChE) 7th International Conference on CRISPR Technologies.
 The company created the SMART platform to overcome a significant hurdle in in vivo gene editing: delivering gene-editing components to tissues other than the liver. Normally, these components exceed the capacity of standard adeno-associated virus (AAV) vectors. However, the SMART system is allegedly small enough to fit in standard AAV vectors, which would solve this problem. Metagenomi anticipates using this technology to explore new neuromuscular targets, through both its own research and development efforts and partnerships.
 
</div>

Metagenomi

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless